Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease
() -- Agios Pharmaceuticals (AGIO) said Tuesday that the US Food and Drug Administration granted Priority Review to its supplemental new drug application for mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease. The company said the Prescription Drug User Fee Act target action date is